Results 41 to 50 of about 106,775 (245)
Insulin and GLP-1 infusions demonstrate the onset of adipose-specific insulin resistance in a large fasting mammal: potential glucogenic role for GLP-1. [PDF]
, 2013 Prolonged food deprivation increases lipid oxidation and utilization, which may contribute to the onset of the insulin resistance associated with fasting.
Crocker, Daniel E +7 more
core +1 more source
PLoS ONE, 2015 AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts +5 more
doaj +1 more source
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists [PDF]
Endocrinology and Metabolism, 2016 Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade.
Yu Mi Kang, Chang Hee Jung
doaj +1 more source
Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2009 The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be used as specific targets for in vivo receptor radiolabeling.The objective of the study was to test ...
Christ, Emanuel +9 more
openaire +5 more sources
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling [PDF]
, 2013 It has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and type 2 diabetes is the most common form. Type 2 diabetes increases the risk of complications such as heart attacks, blindness, amputations and
Venkat Kanamarlapudi
core +1 more source
Actions of glucagon‐like peptide‐1 receptor ligands in the gut
British Journal of Pharmacology, 2021 The incretin hormone glucagon‐like peptide‐1 (GLP‐1) is inactivated by the enzyme dipeptidyl peptidase‐4 even before it leaves the gut, but it seems to act predominantly via activation of intestinal sensory neurons expressing GLP‐1 receptors. Thus, activation of vagal afferents is probably responsible for its effects on appetite and food intake ...
Holst, Jens Juul +2 more
openaire +4 more sources
Neural Regeneration ResearchDiabetic retinopathy is a prominent cause of blindness in adults, with early retinal ganglion cell loss contributing to visual dysfunction or blindness.
Yu-Qi Shao +8 more
doaj +1 more source
Journal of Cardiovascular Development and Disease, 2023 Background: Calcific aortic valve disease (CAVD) is a significant cause of morbidity and mortality among elderly people. However, no effective medications have been approved to slow or prevent the progression of CAVD.
Yangzhao Zhou +10 more
doaj +1 more source
G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets [PDF]
, 2014 It is becoming evident that nutrients and metabolic intermediates derived from such nutrients regulate cellular function by activating a number of cell-surface G-protein coupled receptors (GPCRs).
Brian D. Hudson +6 more
core +2 more sources
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
Journal of DiabetesGlucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac +2 more
doaj +1 more source